根据新的药物洞察力,肿瘤学开始在白血病和肺癌方面对RC220进行两项新的试验。 Race Oncology starts two new trials for RC220 in leukemia and lung cancer, based on new drug insights.

根据对该药物机制的新认识,种族肿瘤学为其RC220药物启动了两个新的临床方案,其对象是急性流质白血病和经EGFR改型的非小细胞肺癌。 Race Oncology has launched two new clinical programs for its drug RC220, targeting acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer, based on new insights into the drug’s mechanism. 这一举措旨在解决高需求癌症地区的治疗抗药性问题,并支持可能的简化监管途径。 The move aims to address treatment resistance in high-need cancer areas and supports a potential streamlined regulatory path. 该公司正在同时推动多个晚期肿瘤学机会。 The company is advancing multiple late-stage oncology opportunities simultaneously. 该公告于2025年11月16日宣布。 The announcement was made on November 16, 2025.